Philips have teamed up with The University of Texas MD Anderson Cancer Centre to provide oncologists with evidence-based therapy and clinical trial guidance through the former’s oncology informatics solutions which provides clinicians with a unified view of therapies and clinical trials in the context of their patient’s unique tumour, and the latter’s Precision Oncology Decision Support (PODS) system which provides clinical information like approved therapies and available clinical trials, based upon genetic alterations within the tumour. The partnership will facilitate physicians across the globe to personalize therapy based on the patient’s genomic profile.
General Manager of Oncology Informatics at Philips, Louis Culot, said: “Driven by the latest therapy breakthroughs, a deeper understanding of cancer biology and an increasing number of clinical trials, oncology practices can provide more options than ever for many patients. Broadening our long-standing collaboration with MD Anderson, Precision Oncology Decision Support becomes available to physicians through the Philips oncology informatics solution, providing the latest actionable information that supports their confident clinical decision-making.”
“Through our collaboration with Philips, we hope to share our clinical experience with physicians around the world and contribute to improving care for patients globally“
Funda Meric-Bernstam, chair of Investigational Cancer Therapeutics at MD Anderson, said: “We developed PODS to enable physicians to better understand and act on genetic variations within each patient’s tumour, making it easier to provide the best treatments possible. Through our collaboration with Philips, we hope to share our clinical experience with physicians around the world and contribute to improving care for patients globally.”